You Should Know These Things About Haemonetics Corporation (HAE)


As of Wednesday close, Haemonetics Corporation’s (NYSE:HAE) stock was up $1.01, moving up 1.22 percent to $84.13. The average number of shares traded per day over the past five days has been 338,240 shares. 5 times new highs have been achieved over the past 5 days, with a $4.40 gain in that time frame. In the last twenty days, the average volume was 505,525, while in the previous 50 days, it was 445,490.

Since last month, HAE stock rose 2.24%. Shares of the company fell to $75.09 on 11/14/22, the lowest level in the past month. A 52-week high of $86.48 was reached on 11/08/22 after having rallying from a 52-week low of $43.50. Since the beginning of this year, HAE’s stock price has risen by 58.62% or $31.09, and marked a new high 40 times. However, the stock has declined by -2.72% since its 52-week high.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


HAE stock investors should be aware that Haemonetics Corporation (HAE) stock had its last reported insider trading activity 31 days ago on Oct 24. Strong Stewart W, the President, Global Hospital of the company, disposed of 75 shares for $80.39 on Oct 24. It resulted in a $6,029 divestment by the insider. Basil Michelle L sold 180 shares at an average price of $80.39 on Oct 24. The insider now owns 32,455 shares following the transaction. On Sep 19, EVP and General Counsel Basil Michelle L sold 11,448 shares at $78.36 apiece. The transaction was valued at $897,065.

Valuation Metrics

Right now, Haemonetics Corporation (HAE) has a P/E ratio of about 50.35. The stock’s beta is 0.36. Besides these, the trailing price-to-sales (P/S) ratio of 3.88, the price-to-book (PB) ratio of 5.88, and the price-to-cash flow ratio of 36.14 may also be considered.

Financial Health

In the three months ended June 29, Haemonetics Corporation’s quick ratio stood at 1.80, while its current ratio was 2.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 1.04, and the total debt-to-equity ratio was 1.12. On the profitability front, the trailing twelve-month gross margin is 53.00% percent. In the year ended June 29, operating margins totaled 12.20%. Based on annual data, HAE earned $505.5 million in gross profit and brought in $993.2 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.00%. Return on equity (ROE) for the past 12 months was 11.60%.

In Haemonetics Corporation’s quarter-end financial report for June 29, it reported total debt of $633.12 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HAE’s revenue rose 19.36% to $261.46 million during the quarter, while net income inched up to $297.49 million. While analysts expected Haemonetics Corporation to report $0.51 quarterly earnings, the actual figure was $0.58 per share, beating the consensus estimate by 13.70%. During the quarter, the company generated $69.68 million in EBITDA. The liabilities of Haemonetics Corporation were 1.14 billion at the end of its most recent quarter ended June 29, and its total debt was $769.99 million. The value of shareholders’ equity is $50.61 million.

Technical Picture

This quick technical analysis looks at Haemonetics Corporation’s (HAE) price momentum. With a historical volatility rate of 35.12%, the RSI 9-day stood at 64.28% on 23 November.

With respect to its five-day moving average, the current Haemonetics Corporation price is up by +5.52% percent or $4.40. At present, HAE shares trade +2.52% above its 20-day simple moving average and +26.53% percent above its 100-day simple moving average. However, the stock is currently trading approximately +7.58% above its SMA50 and +54.20% above its SMA200.

Stochastic coefficient K was 66.99% and Stochastic coefficient D was 54.68%, while ATR was 2.59. Given the Stochastic reading of 79.37% for the 14-day period, the RSI (14) reading has been calculated as 60.56%. As of today, the MACD Oscillator reading stands at 2.54, while the 14-day reading stands at 1.62.

Analyst Ratings

Mizuho launched its rating on Haemonetics Corporation (NYSE: HAE) to a Buy in a note to investors on October 13, 2022. Haemonetics Corporation (HAE) has been rated Overweight by analysts. According to 0 brokerage firms, HAE is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Haemonetics Corporation stock as buy, with 4 recommending it as overweight.


Please enter your comment!
Please enter your name here